Back to top
more

Moderna, Inc. (MRNA)

(Real Time Quote from BATS)

$199.97 USD

199.97
1,596,834

-2.50 (-1.24%)

Updated Jun 18, 2021 11:37 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 15% (213 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Cambridge, MA-based Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies..

The company's mRNA based COVID-19 vaccine, mRNA-1273, is approved for emergency use in several countries as COVID-19 vaccine. The vaccine has been launched in multiple countries and several millions of doses have also been administered. The company has supply agreements worth hundreds of millions of doses with different countries. The company has several early to mid-stage pipeline candidates targeting multiple indications including cancer and cardiovascular. It is also developing a ...

General Information

Moderna, Inc.

200 TECHNOLOGY SQUARE

CAMBRIDGE, MA 02139

Phone: 617-714-6500

Fax: NA

Web: http://www.modernatx.com

Email: ir@modernatx.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2021
Next EPS Date 8/4/2021

EPS Information

Current Quarter EPS Consensus Estimate 6.35
Current Year EPS Consensus Estimate 24.71
Estimated Long-Term EPS Growth Rate 12.10
Next EPS Report Date 8/4/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 202.47
52 Week High 227.71
52 Week Low 54.21
Beta 1.48
20 Day Moving Average 8,362,599.00
Target Price Consensus 162.55

MRNA

% Price Change
4 Week 21.99
12 Week 51.86
YTD 93.81
% Price Change Relative to S&P 500
4 Week 20.18
12 Week 40.62
YTD 72.42
Share Information
Shares Outstanding (millions) 401.53
Market Capitalization (millions) 81,297.33
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio 0.00
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) 8.19
Trailing 12 Months 161.98
PEG Ratio 0.68
EPS Growth
vs. Previous Year 911.43%
vs. Previous Quarter 511.59%
   
Sales Growth
vs. Previous Year 22,989.76%
vs. Previous Quarter 239.38%
   
Price Ratios
Price/Book 21.13
Price/Cash Flow NA
Price / Sales 29.76
ROE
3/31/21 19.76
12/31/20 -30.16
9/30/20 -28.11
ROA
3/31/21 8.49
12/31/20 -17.04
9/30/20 -20.31
Current Ratio
3/31/21 1.39
12/31/20 1.43
9/30/20 2.43
Quick Ratio
3/31/21 1.33
12/31/20 1.42
9/30/20 2.43
Operating Margin
3/31/21 21.90
12/31/20 -92.99
9/30/20 -242.73
Net Margin
3/31/21 21.90
12/31/20 -92.99
9/30/20 -242.73
Pre-Tax Margin
3/31/21 23.41
12/31/20 -92.67
9/30/20 -241.91
Book Value
3/31/21 9.58
12/31/20 6.47
9/30/20 6.97
Inventory Turnover
3/31/21 1.49
12/31/20 0.68
9/30/20 NA
Debt-to-Equity
3/31/21 0.04
12/31/20 0.04
9/30/20 0.04
Debt to Capital
3/31/21 3.47
12/31/20 4.11
9/30/20 3.79